|
|
Residual risk and HDL-cholesterol
|
|
|
|
Is There a Therapeutic Need
|
|
|
|
Selecting ‘promising’ candidates
|
|
|
|
HDL(-c) is ‘a mixed bag
|
|
|
|
Many ways to increase HDL-c
|
|
|
|
Outline HDL-c and CV-protection
|
|
|
|
Quantity versus Quality
|
|
|
|
HDL Increases Cholesterol Flux
|
|
|
|
Static versus Dynamic
|
|
|
|
HDL protection beyond RCT
|
|
|
|
HDL Improves Endothelial Function
|
|
|
|
HDL: carrier or carrier-‘platform‘ ?
|
|
|
|
Summary I protective mechanisms
|
|
|
|
Epidemiology versus Genetics LDL vs HDL
|
|
|
|
Summary II Epidemiology vs Genetics
|
|
|
|
‘Negative’ HDLc trials Revisited
|
|
|
|
AIM HIGH
|
|
|
|
AIM-HIGH
|
|
|
|
ILLUMINATE
|
|
|
|
Reasons for adverse outcome Torcetrapib
|
|
|
|
Off-target effects of Torcetrapib
|
|
|
|
Dal-OUTCOMES Trial
|
|
|
|
Why did dalcetrapib fail
|
|
|
|
Other CETP-Inhibitors
|
|
|
|
Future
|
|
|
|
Lessons HDLc-increasing trials
|
|
|
|
Therapies on the Horizon
|
|
|
|
Targeting cholesterol ‘flux’ by increasing ApoA-I
|
|
|
|
Indications for ‘apo-AI/HDL infusables’
|
|
|
|
Take Home:
|
|
Download as PPT (PPTX 7.5MB)
Share this page with your colleagues and friends: